Novartis files application with FDA for Zometa
Novartis Pharmaceuticals has submitted an application to the Food and Drug Administration, seeking marketing authorization for Zometa in the treatment of bone complications associated with a broad range of tumor types. These include prostate and lung cancer, for which no bisphosphonate therapy is currently approved. The spread of cancerous cells from the original tumor to the bone, can lead to se...Zometa [Novartis Drug] For Treatment Of Paget’s Diseas
Results of the clinical study carried out by Professor Ian Reed and his team from the University of Auckland in New Zealand has found that the drug Zometa manufactured by Novartis treats Paget’s disease// far better than the drug Actonel produced by Procter and Gamble. Paget's disease is a condition in which the bones breaks or becomes weak faster than the normal and the new bone repl...Canine Painkiller unveiled by Novartis
Novartis received approval from the Food and Drug Administration to begin marketing Deramaxx, a canine painkiller, which will be used to relieve post-operative pain in dogs. This drug being produced by a Novartis facility at Puerto Rico //is the result of a development project undertaken by Novartis Animal Health that was run for several years at veterinary clinics, colleges and its manufacturing...Glivec the hot cancer drug from Novartis
Novartis is the world's sixth-largest drugmaker (by sales). Novartis was formed after merger of two Swiss companies, Sandoz Ltd. and Ciba-Geigy."Novartis is emerging as one of the premier powerhouses in the global pharmaceuticals industry," says Richard R. Stover, senior analyst with brokerage Natexis Bleichroeder Inc. in New York. The new cancer drug, Glivec's success led to Novartis...Novartis MS Drug Shows Promising Results
Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication//, for the treatment of patients with relapsing multiple sclerosis (MS). The data, presented at the ECTRIMS/ACTRIMS meeting in Thessalonica, Greece, showed that both patient groups taking FTY720 (1.25 mg and 5 mg) who had experienced a reduction in their annualiz...